Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Other Non-Current Assets: 2011-2024

Historic Other Non-Current Assets for RedHill Biopharma (RDHL) over the last 14 years, with Dec 2024 value amounting to $148,000.

  • RedHill Biopharma's Other Non-Current Assets fell 78.35% to $160,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $160,000, marking a year-over-year decrease of 78.35%. This contributed to the annual value of $148,000 for FY2024, which is 0.68% up from last year.
  • As of FY2024, RedHill Biopharma's Other Non-Current Assets stood at $148,000, which was up 0.68% from $147,000 recorded in FY2023.
  • RedHill Biopharma's 5-year Other Non-Current Assets high stood at $16.2 million for FY2021, and its period low was $147,000 during FY2023.
  • Moreover, its 3-year median value for Other Non-Current Assets was $148,000 (2024), whereas its average is $148,333.
  • In the last 5 years, RedHill Biopharma's Other Non-Current Assets surged by 10,534.21% in 2020 and then slumped by 99.07% in 2022.
  • Over the past 5 years, RedHill Biopharma's Other Non-Current Assets (Yearly) stood at $16.2 million in 2020, then climbed by 0.03% to $16.2 million in 2021, then crashed by 99.07% to $150,000 in 2022, then dropped by 2.00% to $147,000 in 2023, then rose by 0.68% to $148,000 in 2024.